Few research compounds generate as much online certainty as BPC-157. It is described as a healing peptide, a gut peptide, a tendon peptide — sometimes all three in one paragraph. The published record behind those claims is real, but it is also narrow in a way that deserves to be stated plainly: nearly all of it is preclinical, much of it comes from one research group in Zagreb, and no completed randomised controlled trial in humans has been published.

This review separates three things that are often merged: what has actually been demonstrated, what has been proposed but not confirmed, and what regulators have said.

BPC-157 is a synthetic pentadecapeptide — a chain of fifteen amino acids — derived from a protein sequence identified in human gastric juice. "BPC" stands for body protection compound , a name given by the researchers who characterised it, not an official pharmacological classification. It is not an approved medicine anywhere in the world, it has no recognised INN (international nonproprietary name), and it is sold only as a research chemical.

That single fact frames everything else. An approved drug has passed through phased human trials that establish a safety profile, a dosing range and a benefit-risk judgement. BPC-157 has passed through none of them.

The scientific literature on BPC-157 is unusually cohesive because it is unusually concentrated. The group around Predrag Sikirić at the University of Zagreb has produced the large majority of the published work over two decades. Their review papers summarise experiments in rodent models across an unusually wide range of injuries:

Gastrointestinal effects. The earliest work concerned gastric and intestinal lesions — ulcers, fistulas, anastomosis healing — in rats, where BPC-157 given orally or systemically was associated with faster mucosal repair. This is the origin of the "gut peptide" description.

Vascular and ischemia models. A 2021 paper in the World Journal of Gastroenterology reported effects in rats subjected to major vessel occlusion and ischemia-reperfusion injury, which the authors frame through a proposed "cytoprotection" concept.

Tendon, muscle and ligament models. Animal studies from the same group report accelerated healing of transected tendons and muscle crush injuries, which is the basis of its reputation in sports and recovery circles.

Proposed mechanisms include modulation of the nitric oxide system, effects on growth factor expression such as VEGF, and interactions with dopaminergic and serotonergic signalling. These are hypotheses drawn from animal experiments, not established human pharmacology.

The evidence base for BPC-157 is broad in the number of injury models studied and narrow in almost every other dimension: species, research groups, and independent replication.

No completed randomised controlled trial of BPC-157 in humans has been published in a peer-reviewed journal as of September 2026. There are no published Phase 1 safety data establishing a tolerated dose range in humans, no pharmacokinetic profile in human volunteers, and no long-term safety data of any kind.

Claims that BPC-157 "heals tendons" or "repairs the gut" in humans are extrapolations from rodent studies. Extrapolation of this kind fails regularly in drug development: the majority of compounds that look promising in animal models do not replicate in human trials. That is not an argument that BPC-157 could not work in humans; it is the statement that nobody currently knows whether it does.

Two regulatory positions matter and are often blurred together:

WADA. BPC-157 is named on the World Anti-Doping Agency Prohibited List under category S0 — non-approved substances. Any athlete subject to anti-doping rules who uses it risks a violation, regardless of whether a therapeutic effect has ever been demonstrated.

FDA and other medicines regulators. BPC-157 is not approved for any human use. The FDA has repeatedly flagged the safety and quality risks of unapproved peptide drugs, including unknown purity, incorrect identity and contamination, and does not permit them to be marketed as treatments.

Products sold online as BPC-157 are research chemicals outside the medicines supply chain. Their identity and purity are established, at best, by a supplier's certificate of analysis — not by regulatory oversight.

Three conclusions follow directly from the record:

The preclinical literature is genuinely interesting and deserves proper clinical investigation. It has not received it.

Every human-facing claim — healing, recovery, gut repair — currently rests on animal data, mostly from one laboratory.

Because no human dosing or safety data exist, any dosage figure circulating online is without scientific basis, and this publication does not provide one.

BPC-157 is a compound with an unusually wide preclinical footprint and a completely empty human one. The responsible summary is not that it works, and not that it cannot work — it is that the experiments which would answer the question have never been run in people. Until a registered, peer-reviewed human trial exists, BPC-157 belongs in the category its regulators have already placed it in: an unapproved research substance with unresolved safety and efficacy.

The sources above are the primary material this review is based on: the Zagreb group's review papers for the preclinical record, the WADA Prohibited List for the anti-doping position, and FDA communications for the regulatory framing of unapproved peptides.